Influence Of The Intensity Of The Conditioning Regimens On The Risks Of Gvhd In Patients Receiving Rituximab Prophylaxis During Allogeneic Stem Cell Transplantation (Allosct)

Issa F. Khouri,Denai R. Milton,Celina Ledesma,Elias J. Jabbour,Gheath Alatrash,Paolo Anderlini,Amin M. Alousi,Qaiser Bashir,Stefan O. Ciurea,Sharon Hymes,David Marin,Jeffrey J. Molldrem,Amanda L. Olson,Betul Oran,Uday Popat,Muzaffar H. Qazilbash,Gabriela Rondon,Richard E. Champlin,Alison Gulbis

BLOOD（2018）

Cited 0|Views8

No score

Abstract

Purpose: Rituximab (R) use can attenuate the risks of graft-versus-host disease (GVHD) after non-myeloablative allogeneic (NMA) alloSCT. There is a paucity of information on the impact of this strategy in patients receiving myeloablative (MA) conditioning.

Translated text

Key words

allogeneic stem cell transplantation,rituximab prophylaxis,gvhd

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined